Novel approaches to plant drug discovery based on high throughput pharmacological screening and genetic manipulation

被引:28
|
作者
Littleton, J
Rogers, T
Falcone, D
机构
[1] Univ Kentucky, KTRDC, Lexington, KY 40546 USA
[2] Univ Massachusetts, Dept Biol Sci, Lowell, MA 01854 USA
关键词
drug discovery; plants; nicotinic acetylcholine receptors; radioligand binding; NICOTINIC ACETYLCHOLINE-RECEPTORS; ALPHA-BUNGAROTOXIN; ALZHEIMERS-DISEASE; BINDING-SITES; RAT-BRAIN; NEUROPROTECTION; (-)-NICOTINE;
D O I
10.1016/j.lfs.2005.09.013
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Plants are potentially important for novel therapeutic drug leads, but the slowness of conventional methods for investigation of plants limits enthusiasm in the pharmaceutical industry. To overcome some of the drawbacks, we have applied high throughput pharmacological screening (HTPS) to crude plant extracts. Using a "differential smart screen", (DSS) the spectrum of activity contained in a crude extract is measured at several closely related receptor subtypes. This spectrum is then compared to that of known compounds. A unique spectrum suggests that the extract merits further investigation. Evaluation of species and environmental libraries of whole plants has demonstrated the value of this approach for rapid prioritization of plants for investigation. In addition, genomic and genetic manipulation of plants and plant cell cultures can increase the value of DSS. For example, the whole genomic potential of a plant species for biodiversity can be accessed by using gain of function mutations to generate a "functional genomics library" of mutant clonal cultures, and the bioactivity of these cultures tested by DSS. Clones that overproduce activity differing from the wild-type plant can be identified in this way. This "Natural Products Genomics" (NPG) strategy is limited by the massive numbers of clonal cultures that are required to cover all possible gain-of-function mutations. The rapidity and efficiency of this process can be improved by using transgenic plants expressing appropriate mammalian proteins. These may be designed to make the plant cell resemble a human cell for a specific form of toxicity. Now, "unnatural selection" of resistant mutant clones can be used to provide a sub-population potentially enriched in useful compounds. Alternatively, transgenic plant cells can be used for "in situ screening" in which a mammalian receptor protein, linked to a reporter construct, such as green fluorescent protein, is expressed. Clonal cultures that produce ligands for this receptor can now be rapidly identified visually in an ultra-HTPS. Overall, our aim is to use pharmacological screening, together with functional genomic approaches, to make plant drug discovery competitive with combinatorial chemistry. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:467 / 475
页数:9
相关论文
共 50 条
  • [21] Developments with bead-based screening for novel drug discovery
    Pei, Dehua
    Kubi, George Appiah
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (11) : 1097 - 1102
  • [22] Streamlining the Drug Discovery Process by Integrating Miniaturization, High Throughput Screening, High Content Screening, and Automation on the CellChip™ System
    Kapur, Ravi
    Giuliano, Kenneth A.
    Campana, Martha
    Adams, Terri
    Olson, Keith
    Jung, David
    Mrksich, Milan
    Vasudevan, Chandrasekaran
    Taylor, D. Lansing
    BIOMEDICAL MICRODEVICES, 1999, 2 (02) : 99 - 109
  • [23] Streamlining the Drug Discovery Process by Integrating Miniaturization, High Throughput Screening, High Content Screening, and Automation on the CellChip™ System
    Ravi Kapur
    Kenneth A. Giuliano
    Martha Campana
    Terri Adams
    Keith Olson
    David Jung
    Milan Mrksich
    Chandrasekaran Vasudevan
    D. Lansing Taylor
    Biomedical Microdevices, 1999, 2 : 99 - 109
  • [24] Chemical genetic approaches to kinase drug discovery
    Gallion, SL
    Qian, DP
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (05) : 638 - 645
  • [25] Upscaling and automation of electrophysiology: Toward high throughput screening in ion channel drug discovery
    Asmild, M
    Oswald, N
    Krzywkowski, KM
    Friis, S
    Jacobsen, RB
    Reuter, D
    Taboryski, R
    Kutchinsky, J
    Vestergaard, RK
    Schroder, RL
    Sorensen, CB
    Bech, M
    Korsgaard, MPG
    Willumsen, NJ
    RECEPTORS & CHANNELS, 2003, 9 (01) : 49 - 58
  • [26] Discovery of a new drug -: From target identification to ultra-high-throughput screening
    Golz, Stefan
    Hueser, Joerg
    CLINICAL LABORATORY, 2007, 53 (1-2) : 77 - 79
  • [27] Accelerating Drug Discovery With High-Throughput Crystallographic Fragment Screening and Structural Enablement
    Fearon, Daren
    Powell, Ailsa
    Douangamath, Alice
    Dias, Alexandre
    Tomlinson, Charles W. E.
    Balcomb, Blake H.
    Aschenbrenner, Jasmin C.
    Aimon, Anthony
    Barker, Isabel A.
    Brandão-Neto, José
    Collins, Patrick
    Dunnett, Louise E.
    Fairhead, Michael
    Gildea, Richard J.
    Golding, Mathew
    Gorrie-Stone, Tyler
    Hathaway, Paul V.
    Koekemoer, Lizbé
    Krojer, Tobias
    Lithgo, Ryan M.
    Maclean, Elizabeth M.
    Marples, Peter G.
    Ni, Xiaomin
    Skyner, Rachael
    Talon, Romain
    Thompson, Warren
    Wild, Conor F.
    Winokan, Max
    Wright, Nathan David
    Winter, Graeme
    Shotton, Elizabeth J.
    von Delft, Frank
    Applied Research, 2025, 4 (01):
  • [28] Exploiting high-throughput ion channel screening technologies in integrated drug discovery
    Treherne, JM
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (04) : 397 - 406
  • [29] High throughput molecular dynamics for drug discovery
    Nathaniel Stanley
    Gianni De Fabritiis
    In Silico Pharmacology, 3 (1)
  • [30] Discovery of novel acetylcholinesterase inhibitors through integration of machine learning with genetic algorithm based in silico screening approaches
    Khan, Mohd Imran
    Taehwan, Park
    Cho, Yunseong
    Scotti, Marcus
    Priscila Barros de Menezes, Renata
    Husain, Fohad Mabood
    Alomar, Suliman Yousef
    Baig, Mohammad Hassan
    Dong, Jae-June
    FRONTIERS IN NEUROSCIENCE, 2023, 16